礼来公布口服降糖药积极结果,或年底前提交用于体重管理上市申请

澎湃新闻
18 Apr

“GLP-1双雄”之一的礼来公布口服小分子GLP-1药物orforglipron在糖尿病领域的积极研究结果,也让行业对口服小分子减肥药充满期待。当地时间4月17日,礼来公布3期临床研究ACHIEVE-1的积极顶线结果,该研究评估了orforglipron对比安慰剂,在饮食控制和运动基础上血糖控制仍不佳的2型糖尿病患者中的安全性和有效性。礼来称,该药是首个成功完成3期试验、对饮食或饮水不加以限制的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10